Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 147

  • 3 898 clinical trials
  • 1 548 recruiting
  • 703 conditions
  • 31 countries

Conditions in this area

703 conditions with trials, the busiest first

Non-small cell lung cancer327Breast cancer168Plasma cell myeloma164Neoplasm158Acute myeloid leukaemia132Neoplasm malignant129Colorectal cancer metastatic105Prostate cancer101Ovarian cancer91Colorectal cancer89Hepatocellular carcinoma89Breast cancer metastatic84Non-small cell lung cancer metastatic82Malignant melanoma79Chronic lymphocytic leukaemia77Triple negative breast cancer69Squamous cell carcinoma of head and neck68Hormone receptor positive HER2 negative breast cancer62Non-small cell lung cancer stage IV57Pancreatic carcinoma57Hormone-refractory prostate cancer56Gastric cancer55Bladder cancer54Endometrial cancer53+679

Clinical trials in Neoplasms benign, malignant and unspecified (incl cysts and polyps)

3 898 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

3 898 clinical trials

Gastrointestinal carcinoma+4

Not yet recruiting

A Study Using Indocyanine Green Fluorescence Imaging to Help Surgeons Better Identify Tumor Edges During Cancer Surgery in Patients with Solid Tumors

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Indocyanine Green
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Hormone-dependent prostate cancer+1

Not yet recruiting

Study of Darolutamide to Increase PSMA Protein Expression in Patients with Hormone Sensitive Prostate Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Darolutamide
  • Sponsor:Amsterdam UMC Stichting

Lung neoplasm malignant

Not yet recruiting

Testing F-18-AraG imaging scan reliability in patients with lung cancer using repeat scans

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Nelarabine
  • Sponsor:Amsterdam UMC Stichting

Breast cancer

Not yet recruiting

Study of 6qc-ICG applied to the skin during breast cancer surgery to help surgeons see tumor edges in patients having breast conserving operations

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:6QC-ICG
  • Sponsor:Leids Universitair Medisch Centrum (LUMC)

Non-small cell lung cancer

Not yet recruiting

A study comparing 68Ga-FAPI-46 PET scan with standard 18F-FDG PET scan and brain MRI for staging in patients with newly diagnosed non-small cell lung cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:(S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate
  • Sponsor:Academisch Ziekenhuis Maastricht

Rectal cancer

Not yet recruiting

A Study of Watchful Waiting After Chemotherapy and Radiotherapy Compared to Surgery for Patients with Early Rectal Cancer Using Capecitabine

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Vaestra Goetalandsregionen

Breast cancer female

Not yet recruiting

Study of abemaciclib and its connection to severe diarrhea in patients with hormone receptor-positive breast cancer at high risk of return

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Centre Hospitalier Universitaire De Poitiers

Acute lymphocytic leukaemia+2

Not yet recruiting

A Study of Blinatumomab in Children with Relapsed or Treatment-Resistant B Cell Acute Lymphoblastic Leukemia with Remaining Disease Traces

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Blinatumomab
  • Sponsor:Amgen Inc.

Rectal adenocarcinoma

Not yet recruiting

Study of drug combination with radiotherapy versus radiotherapy alone for locally advanced rectal cancer in patients 75 years and older

Registered drugNo placebo
Countries:FranceFrance
  • Participants:65+ years
  • Substances:Calcium Levofolinate
  • Sponsor:Unicancer

Non-small cell lung cancer

Not yet recruiting

Study of cemiplimab with or without chemotherapy for non-small cell lung cancer patients with high PD-L1 levels to reduce rapid disease progression

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Universita' Vita-salute S. Raffaele

Non-small cell lung cancer

Not yet recruiting

Testing OMTX705 Combined with Carboplatin, Pemetrexed, and Tislelizumab for Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Carboplatin
  • Sponsor:Oncomatryx Biopharma S.A.

Non-small cell lung cancer

Not yet recruiting

Study of Izalontamab Brengitecan versus Platinum-based Chemotherapy for Patients with EGFR-mutated Non-small Cell Lung Cancer after EGFR Inhibitor Treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Substances studied in this area

The therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.

Pembrolizumab462 clinical trialsCarboplatin340 clinical trialsCisplatin285 clinical trialsPaclitaxel263 clinical trialsFluorouracil237 clinical trialsOxaliplatin227 clinical trialsNivolumab217 clinical trialsDexamethasone169 clinical trialsBevacizumab163 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.